Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody
- PMID: 1433529
- PMCID: PMC240465
- DOI: 10.1128/JVI.66.12.7538-7542.1992
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody
Abstract
The third variable region (V3) of the HIV-1 gp120 envelope glycoprotein is thought to induce potent neutralizing antibodies which are generally defined as type specific and reactive with individual viral isolates. In contrast, the CD4-binding domain is thought to induce neutralizing antibodies that are group specific and capable of neutralizing all isolates of HIV-1. However, in this study, we used a panel of human monoclonal antibodies to these regions of gp120 which displays specificities and neutralizing activities that challenge these tenets. In particular, we used a human monoclonal antibody to the V3 domain with exceptionally potent and broad neutralizing activity against many diverse HIV-1 isolates. The anti-CD4-binding domain antibodies, on the other hand, showed a more restricted pattern of activity.
Similar articles
-
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.J Virol. 1993 Oct;67(10):6179-91. doi: 10.1128/JVI.67.10.6179-6191.1993. J Virol. 1993. PMID: 7690420 Free PMC article.
-
Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.J Virol. 1994 Aug;68(8):4821-8. doi: 10.1128/JVI.68.8.4821-4828.1994. J Virol. 1994. PMID: 7518527 Free PMC article.
-
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.J Acquir Immune Defic Syndr (1988). 1992;5(6):591-9. J Acquir Immune Defic Syndr (1988). 1992. PMID: 1588493
-
Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.Curr Opin HIV AIDS. 2009 Mar;4(2):112-7. doi: 10.1097/COH.0b013e328322f95e. Curr Opin HIV AIDS. 2009. PMID: 19339949 Free PMC article. Review.
-
Candidate antibody-based therapeutics against HIV-1.BioDrugs. 2012 Jun 1;26(3):143-62. doi: 10.2165/11631400-000000000-00000. BioDrugs. 2012. PMID: 22462520 Free PMC article. Review.
Cited by
-
Exploring the Human Cytomegalovirus Core Nuclear Egress Complex as a Novel Antiviral Target: A New Type of Small Molecule Inhibitors.Viruses. 2021 Mar 12;13(3):471. doi: 10.3390/v13030471. Viruses. 2021. PMID: 33809234 Free PMC article.
-
HIV p24 as scaffold for presenting conformational HIV Env antigens.PLoS One. 2012;7(8):e43318. doi: 10.1371/journal.pone.0043318. Epub 2012 Aug 17. PLoS One. 2012. PMID: 22912852 Free PMC article.
-
Display of the HIV envelope protein at the yeast cell surface for immunogen development.PLoS One. 2018 Oct 18;13(10):e0205756. doi: 10.1371/journal.pone.0205756. eCollection 2018. PLoS One. 2018. PMID: 30335821 Free PMC article.
-
Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.J Virol. 2006 Jul;80(14):7127-35. doi: 10.1128/JVI.02619-05. J Virol. 2006. PMID: 16809318 Free PMC article.
-
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.J Virol. 2000 Nov;74(22):10670-80. doi: 10.1128/jvi.74.22.10670-10680.2000. J Virol. 2000. PMID: 11044111 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials